Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
|
|
- Donald Carr
- 7 years ago
- Views:
Transcription
1 The American Journal of Surgery 190 (2005) George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald, M.D., Melvin J. Silverstein, M.D.*, Helen Mabry, M.D., Brenda Moorthy, M.D., Wei Ye, M.S., Melinda S. Epstein, Ph.D., Dennis Holmes, M.D., Howard Silberman, M.D., Michael Lagios, M.D. USC Norris Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave., Room 7415, Los Angeles, CA , USA Manuscript received June 5, 2005; revised manuscript June 10, 2005 Presented at the Sixth Annual Meeting of the American Society of Breast Surgeons, Los Angeles, California, March 16 20, 2005 Abstract Background: Margin width has been shown previously to be the most important predictor of local treatment failure after breast conservation for ductal carcinoma in situ (DCIS). Methods: Five variables thought to be associated with local recurrence were evaluated by univariate and multivariate analysis in 455 nonrandomized patients with DCIS treated with excision alone. Results: Multivariate analysis showed that margin width, age, nuclear grade, and tumor size all were independent predictors of local recurrence, with margin width as the single most important predictor. After adjusting for all other predictors the likelihood of local recurrence for patients with margins less than 10 mm was 5.39 times as much as that for patients with margins of 10 mm or more (95% confidence interval, ). Conclusions: Margin width, the distance between DCIS and the closest inked margin, was the single most important predictor of local recurrence. As margin width increases, the risk for local recurrence decreases Excerpta Medica Inc. All rights reserved. Keywords: Ductal carcinoma in situ; Margin width; Local recurrence risk; Treatment failure Approximately half of all local treatment failures after breast conservation therapy for ductal carcinoma in situ (DCIS) are invasive cancer and therefore a potential threat to life [1 4]. Preventing local recurrence is of paramount importance. Numerous factors including margin width, nuclear grade, presence of comedo necrosis, age, and treatment have been shown to influence the probability of local recurrence. In patients treated with excision alone, margin width was shown previously to exert a greater effect on risk for recurrence than nuclear grade, histologic type, patient age, or tumor size [5,6]. Previous prospective randomized trials that investigated the risk for local recurrence after conservative therapy for DCIS did not collect margin width measurements routinely in a standardized prospective fashion [7 11]. For example, the European Organization for Research and Treatment (EORTC) only recorded exact margin width in 5% of pathology reports. The National Surgical Adjuvant Breast and Bowel Project (NSABP) has not published any data regarding margin width. Margin width cannot be determined retrospectively if the specimens were not inked, completely sampled, or sequentially submitted. This study stratified margin widths in a group of patients with DCIS who were treated by excision alone, and calculated the relationship of margin width to the risk for local recurrence. The goal was to determine the effect of increasing margin width on local treatment failure. Methods * Corresponding author. Tel.: ; fax: address: melsilver9@aol.com From 1972 to 2004, 445 patients with pure DCIS were treated with excision alone. The surgical margins were mea /05/$ see front matter 2005 Excerpta Medica Inc. All rights reserved. doi: /j.amjsurg
2 522 H.R. MacDonald et al. / The American Journal of Surgery 190 (2005) sured in every specimen. An effort was made to excise all suspicious lesions completely and to process all excised tissue. Needle localization, intraoperative specimen radiography, and correlation with the preoperative mammogram were performed for all cases involving nonpalpable lesions (95% of cases). The margins of the specimen were inked or dyed and serially sectioned at 2- to 3-mm intervals. Tissue sections were arranged and processed in sequence. Pathologic evaluation included histologic subtype, nuclear grade, the presence or absence of comedo necrosis, the maximum size of the lesion, and margin width. Margin width was determined by direct measurement or ocular micrometry. The closest single distance between DCIS and an inked margin was reported. Tumors were divided into groups by margin width: 0 mm (tumor transected), 0.1 to 0.9 mm, 1.0 to 1.9 mm, 2.0 to 2.9 mm, 3.0 to 5.9 mm, 6.0 to 9.9 mm, and 10 mm or greater. Patients who underwent re-excision, and in whom no additional DCIS was found, were scored as having 10-mm margins or greater. Tumors were divided into 3 groups by nuclear grade: nuclear grade 1 low; nuclear grade 2 intermediate; nuclear grade 3 high. Comedo necrosis was considered present for any architectural pattern of DCIS in which a central zone of necrotic debris with karyorrhexis was identified. Tumors were divided into 2 groups by the presence or absence of any amount of comedo necrosis. Age was analyzed and data were separated into 3 groups: 39 years and younger, 40 to 60 years, and 61 years and older. All patients with DCIS and known margin widths were included in the study. The outcome studied was the time to local recurrence, which was calculated from the date of diagnosis to the date of local recurrence. Because of the difficulty of accurately differentiating between a true local recurrence and a new cancer in another quadrant of the breast, all ipsilateral breast cancer events were scored as local recurrences. Patients who did not experience a local recurrence were censored at the date of their last follow-up evaluation or death. Kaplan-Meier estimates of the probabilities of remaining free of local recurrence were calculated at 5 and 8 years. The Greenwood formula was used to calculate the standard errors. Both univariate and multivariate Cox regression analyses were performed for surgical margin, age at diagnosis, tumor size, nuclear grade, and the presence of comedo necrosis. The proportional hazard assumption was checked using Schoenfeld residuals. The partial likelihood ratio test based on the Cox model was used to calculate P values (all 2-sided). Results A total of 445 patients were treated for DCIS with excision alone. Seventy-nine (17%) patients experienced local recurrences, of which 26 (33%) were invasive. The median follow-up period was 57 months. The median tumor size was 10 mm. Among patients who experienced local recurrences, the median time to local recurrence was 26 months. There were 79 ipsilateral breast cancer events after initial treatment, 72 of which were in the same quadrant as the original lesion (91%). One patient developed metastatic breast cancer and died of cancer. Twenty-three additional patients died from non breast cancer related causes. Table 1 shows a univariate analysis of local recurrence risk as affected by margin width, high nuclear grade, younger age, greater tumor size, and the presence of comedo necrosis. All were associated significantly with greater risk for developing local recurrence (P.001). Only 9 of 197 (4.6%) patients with a greater than 10-mm margin experienced local failure. For patients with 10-mm or greater margins, the probability of remaining free of local recurrence at 5 years was 93%. For patients with 1.0- to 1.9-mm margins it was 73%. For patients with transected margins it was 48%. The relative risk of developing a local recurrence stratified by surgical margin was plotted as a continuous variable (Fig. 1). A clear trend emerged: as margin width increased, the hazard ratio for local failure decreased (Fig. 1). Table 1 breaks margin width into 7 groups and, overall, the risk for developing local recurrence decreased as the margin width increased. Table 2 shows the mean tumor size for the 7 different margin widths. Patients with 3.0- to 5.9-mm margins had a higher relative risk than those with 2.0- to 2.9-mm margins, possibly owing to their larger mean tumor size (19.7 vs 9.1 mm) (Table 2) and small numbers of patients in each group. Multivariate analysis showed that the margin width had the smallest P value and the greatest hazard ratio and was thus the most significant predictor of local recurrence (Table 3). Age at diagnosis, nuclear grade, and tumor size also remained significant predictors of local recurrence by multivariate analysis although the presence of necrosis no longer was significant. The effect of margin width was independent of age at diagnosis, nuclear grade, and tumor size. After adjusting for all other predictors the likelihood of local recurrence for patients with margins less than 10 mm was 5.39 times as much as that for patients with margins of 10 mm or more (95% confidence interval, ). A comparison of hazard ratios of tumor predictors also shows the dominant effect of margin width on local recurrence risk (Table 4). The hazard ratio for developing local recurrence if margins were transected was 7.69 times as great as the risk if margin widths were 10 mm or greater. The hazard ratios for other predictors were less: for age at diagnosis of less than 40 years versus older than 60 years the relative hazard ratio was For tumor with nuclear grade III versus grades I or II the relative hazard ratio was For tumor size at 40 mm versus 0 mm the relative hazard ratio was 2.81.
3 H.R. MacDonald et al. / The American Journal of Surgery 190 (2005) Table 1 Univariate analysis of predictors of local recurrence of DCIS Total N/no. of events Relative hazard ratio (95% confidence interval) P value Probability of remaining free of local recurrence at 5 years ( SE) Probability of remaining free of local recurrence at 8 years ( SE) Margin (transected) 32/ % 11% 39% 12% /18.61 ( ) 63% 8% 58% 9% /7.58 ( ) 73% 12% 49% 16% /20.21 (.10.42) 81% 5% 78% 5% /8.35 (.15.83) 64% 11% 64% 11% /2.20 (.05.87) 91% 9% 61% 25% /9.07 (.03.15) 93% 3% 91% 3% Age (y) / % 11% 47% 12% /59.46 (.25.86) 80% 3% 74% 3% /8.18 (.07.43) 90% 4% 90% 4% Nuclear grade.001 I/II 258/ % 2% 87% 3% III 187/ ( ) 64% 4% 59% 5% Tumor size (mm) / % 4% 86% 5% / ( ) 89% 3% 80% 5% / ( ) 78% 7% 78% 7% / ( ) 63% 9% 63% 9% / ( ) 73% 8% 68% 9% / ( ) 66% 11% 55% 14% 50 19/ ( ) 49% 17% Necrosis.001 No 157/ % 3% 89% 3% Yes 288/ ( ) 73% 3% 66% 4% Comments The treatment of DCIS with excision alone has psychologic and physical advantages for the patient over mastectomy or excision plus radiotherapy. However, excision alone is accompanied by an increase in risk for local treatment failure [1,8,12]. In other studies, approximately 50% of local recurrences are invasive cancer [1 4]. In our dataset, 33% of local recurrences were invasive cancer. Although no randomized trial has shown any survival benefit for more aggressive treatment, preventing a local invasive recurrence is of great importance. When an invasive recurrence occurs an almost completely curable noninvasive lesion has advanced to a potentially less curable form with a higher potential mortality rate. An analysis of our data show that as the margin width increased, the probability of local recurrence decreased. This trend was not affected by patient age or nuclear grade. Tumor size may exert a confounding effect on the local recurrence risk for patients with 2.0- to 2.9-mm and 3.0- to 5.9-mm margin widths because the former group had smaller tumors and lower hazard ratios than the latter. This represents a reversal of the overall trend of increasing margin width and decreasing local recurrence risk. Multivariate analysis provides a mathematic model that establishes both tumor size and margin width as independent predictors of local recurrence risk. However, in vivo, neither factor exists alone. Both factors exert their influence in all patients. Small numbers of patients in each margin-width stratification are another possible confounding factor. If wide margins are obtained, regardless of other factors, the probability of local recurrence remains small. With greater than 10-mm margins, the probability of remaining recurrence free at 8 years is greater than 90% without postoperative radiotherapy. With less than 1-mm margins the probability of remaining recurrence free at 8 years with excision alone decreases to 58%. Simply defining margins as nontransected allows a broad range of margin widths to be considered acceptable or clear. Clear but very close margins are associated with an increased probability of local recurrence. Additionally, the risk for experiencing a local recurrence is 7 times greater for patients with transected margins than for those with greater than 10-mm margins. The most likely cause of local recurrence after excision alone for DCIS is inadequate surgery resulting in residual disease. Most local recurrences after breast conservation therapy for DCIS occur at or near the primary lesion. In our series, 91% of local recurrences after excision alone were in the same quadrant as the original lesion. Residual disease appears to be best predicted by margin width. Wide margin width increases the probability of complete excision. In previously reported data from 181 patients with DCIS treated with wide excision, 43% of patients with clear margins ( 1 mm from the inked margin) had residual disease
4 524 H.R. MacDonald et al. / The American Journal of Surgery 190 (2005) Fig. 1. Hazard ratio of local recurrence versus margin width. The solid line is the relative hazard ratio function calculated using the Cox regression model based on log transformed (margin width 1). The open circles are the categorized relative hazard ratios calculated using the Cox regression model based on categorized margin-width groups. Both used transected margin (margin width 0 mm) as the reference. The categorized relative hazard ratios are plotted against the mean margin width in each margin-width group using the equation hazard ratio (margin width 1) Table 2 Tumor size stratified by margin width in patients with DCIS Margin (mm) N Mean tumor size (mm) 0 (transected) on re-excision or mastectomy [13]. These patients would have had clear margins if judged by NSABP standards (tumor not transected). Approximately 76% of patients with DCIS less than 1 mm from the inked original margins had residual disease on re-excision or mastectomy. In 2002, Neuschatz et al [14] analyzed re-excision specimens of 253 patients treated with lumpectomy for DCIS and re-excised for margins of 2 mm or less per institutional policy. Sixtythree percent of patients with transected margins had residual DCIS at re-excision. Forty-one percent of patients with greater than 0- to 1-mm margins had residual DCIS at re-excision. Thirty-one patients with greater than 1- to 2-mm margins had residual DCIS at re-excision. The NSABP B-17 trial did not require marking of margins, complete tissue processing, specimen radiography, or margin-width measurement. In their initial report, 40% of the patients did not have a size measurement [7]. The lack of these data makes it impossible for the NSABP study to determine size and margin width criteria for optimal excision. The EORTC and UK DCIS trials also were not de- Table 3 Multivariate analysis of predictors of local recurrence of DCIS Variable Relative hazard ratio Chi-square Degree of freedom P value Log transformed.42 (.32.56)* margin Age (y) ( ) (.09.58) Nuclear grade I/II 1.00 III 3.44 ( ) Log transformed 1.21 ( ) tumor size Necrosis No 1.00 Yes 1.16 ( ) * Hazard ratio for each unit increase in natural log (margin width in mm 1). Hazard ratio for increase in tumor size by 100%.
5 H.R. MacDonald et al. / The American Journal of Surgery 190 (2005) Table 4 Relative hazard ratios of local recurrence of predictors Variable Margin 0 vs 10 mm 7.69 Age 40 vs 60 y 4.17 Nuclear grade III vs I/II 3.44 Tumor size 40 vs 1 mm 2.81 signed to identify subgroups at high risk for local treatment failure [9 11]. The study designs of all the previously randomized trials proved the benefit of postoperative radiotherapy across a wide range of patients but they cannot be used to select groups of patients who are at minimal risk for local recurrence without postoperative radiation therapy. Further studies such as the one presented here are needed to refine surgical goals for optimally excising DCIS when treated conservatively. Margin width is the single most important factor in predicting local recurrence after excision alone for DCIS. As margin width increases, the probability of local recurrence decreases. A high rate of local control can be achieved when the margin width is 10 mm or greater, regardless of high nuclear grade, large tumor size, or young patient age. References Hazard ratio [1] Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995;31: [2] Silverstein MJ, Lagios MD, Martino S, et al. Outcome after local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998;16: [3] Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected ductal carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63: [4] Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14: [5] Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340: [6] Boland GP, Chan KC, Knox WF, et al. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003;90: [7] Fisher B, Constantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328: [8] Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic finding from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17. Cancer 1999;86: [9] Julien JP, Bijker N, Fentiman I, et al. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: first results of EORTC randomized phase III trial Lancet 2000;355: [10] Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer Trial J Clin Oncol 2001;19: [11] Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet 2003;362: [12] Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345: [13] Silverstein MJ, Gierson ED, Colburn WJ, et al. Can intraductal breast carcinoma be excised completely by local excision. Cancer 1994;73: [14] Neuschatz AC, DiPetrillo T, Safaii H, et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 2002;94:
The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast
The American Journal of Surgery 186 (2003) 337 343 Scientific paper The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast Melvin J. Silverstein, M.D.*
More informationDuctal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194
Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194 Sabin B. Motwani, MD 1 ; Sharad Goyal, MD 1 ; Meena S. Moran, MD 2 ; Arpit Chhabra, BS
More informationUnderstanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
More informationductal carcinoma in situ (DCIS)
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre
More informationDuctal Carcinoma In Situ of the Breast: Controversial Issues
Ductal Carcinoma In Situ of the Breast: Controversial Issues MELVIN J. SILVERSTEIN The Breast Center*, Van Nuys, California, USA Key Words. DCIS Ductal carcinoma in situ Noninvasive breast cancer Intraductal
More informationManagement of Ductal Carcinoma in Situ of the Breast
Evidence-based Series 1-10 Version 2.2006 IN REVIEW A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Management of Ductal Carcinoma in Situ of the Breast W.
More informationLocal Recurrences After Conservative Treatment of Ductal Carcinoma-In-Situ of the Breast Without Radiotherapy: The Effect of Age
Annals of Surgical Oncology (Ó 2006) DOI: 10.1245/ASO.2006.05.044 Local Recurrences After Conservative Treatment of Ductal Carcinoma-In-Situ of the Breast Without Radiotherapy: The Effect of Age Arjan
More informationPublished Ahead of Print on September 16, 2013 as 10.1200/JCO.2013.49.5077. J Clin Oncol 31. 2013 by American Society of Clinical Oncology
Published Ahead of Print on September 16, 213 as 1.12/JCO.213.49.577 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.213.49.577 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationThe management of ductal carcinoma in situ of the breast
The management of ductal carcinoma in situ of the breast K A Skinner and M J Silverstein Keck School of Medicine, University of Southern California, USC/Norris Comprehensive Cancer Center, 1441 Eastlake
More informationADJUVANT RADIATION THERAPY FOR DUCTAL CARCINOMA IN SITU
ADJUVANT RADIATION THERAPY FOR DUCTAL CARCINOMA IN SITU Effective Date: May 2015 The recommendations contained in this guideline are a consensus of the Alberta Provincial Breast Tumour Team and are a synthesis
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationDuctal Carcinoma In Situ of the Breast
Melchior de Hondecoeter, 1670. A Golden Eagle Attacking a Menagerie of Birds (detail). From the collection of Dr. and Mrs. Gordon Gilbert of St. Petersburg, FL. Ductal Carcinoma In Situ of the Breast Elisabeth
More informationRisk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case Control Study
Ann Surg Oncol DOI 10.1245/s10434-015-4641-x ORIGINAL ARTICLE BREAST ONCOLOGY Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case Control
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationGuidelines for the treatment of breast cancer with radiotherapy
London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal
More informationPROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL
Oncoplastic breast conservation surgery Melvin J Silverstein C H A P T E R 5 Introduction Oncoplastic breast conservation surgery combines oncologic principles with plastic surgical techniques. But it
More informationGentest für DCIS? SENOLOGIE update 2015 21. Mai 2015 Kongress-Eventzentrum LAKE SIDE Prof. Bernhard Pestalozzi, Klinik für Onkologie, USZ
Gentest für DCIS? SENOLOGIE update 2015 21. Mai 2015 Kongress-Eventzentrum LAKE SIDE Prof. Bernhard Pestalozzi, Klinik für Onkologie, USZ Gliederung Einführung: Multigen Profile OncotypeDX (21-gene score)
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationAmerican College of Radiology ACR Appropriateness Criteria DUCTAL CARCINOMA IN SITU
American College of Radiology ACR Appropriateness Criteria Date of origin: 1996 Last review date: 2014 DUCTAL CARCINOMA IN SITU Expert Panel on Radiation Oncology Breast: Seth A. Kaufman, MD 1 ; Eleanor
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: Revised: This policy applies
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationImpact of radiation therapy on survival in patients with triple negative breast cancer
548 Impact of radiation therapy on survival in patients with triple negative breast cancer LAUREN T. STEWARD 1, FENG GAO 2, MARIE A. TAYLOR 3 and JULIE A. MARGENTHALER 1 1 Department of Surgery; 2 Division
More informationPATIENT SUBSETS WITH T1-T2, NODE-NEGATIVE BREAST CANCER AT HIGH LOCOREGIONAL RECURRENCE RISK AFTER MASTECTOMY
doi:10.1016/j.ijrobp.2004.09.013 Int. J. Radiation Oncology Biol. Phys., Vol. 62, No. 1, pp. 175 182, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front
More informationArticles. Early Breast Cancer Trialists Collaborative Group (EBCTCG)* www.thelancet.com Vol 366 December 17/24/31, 2005 2087
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationCLINICAL NEGLIGENCE ARTICLE: THE DETECTION & TREATMENT OF BREAST CANCER & CLAIMS FOR LOSS OF LIFE EXPECTANCY IN CLINICAL NEGLIGENCE CASES
CLINICAL NEGLIGENCE ARTICLE: THE DETECTION & TREATMENT OF BREAST CANCER & CLAIMS FOR LOSS OF LIFE EXPECTANCY IN CLINICAL NEGLIGENCE CASES Reports relating to the detection and treatment of breast cancer
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationMammography Education, Inc.
Mammography Education, Inc. 2011 LÁSZLÓ TABÁR, M.D.,F.A.C.R (Hon) 3D image of a milk duct MULTIMODALITY DETECTION and DIAGNOSIS of BREAST DISEASES PRAGUE, Czech Republic Crown Plaza, Prague June 29 - July
More informationDoes Resection of an Intact Breast Primary Improve Survival in Metastatic Breast Cancer?
rvival in Metastatic Breast Cancer? Review Article [1] July 01, 2007 By Seema A. Khan, MD [2] The recommended primary treatment approach for women with metastatic breast cancer and an intact primary tumor
More informationInfrared Thermography Not a Useful Breast Cancer Screening Tool
Contact: Jeanne-Marie Phillips Sharon Grutman HealthFlash Marketing The American Society of Breast Surgeons 203-977-3333 877-992-5470 Infrared Thermography Not a Useful Breast Cancer Screening Tool Mammography
More informationTHREE EVENTS OCCURRED during the 1980s that
Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less By Bernard Fisher, John Bryant,
More informationINTERDISCIPLINARY CONFERENCE. Florence/Firenze, Italy Nov 27-29, 2012 Centro Congressi al Duomo, Firenze BREAST SEMINAR SERIES
Since breast cancer is not a systemic disease from inception, when the imagers find in situ and 1-14 mm invasive breast cancer, it is the surgeon, specialized in the treatment of breast diseases, who should
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationNational Breast and Ovarian Cancer Centre and Royal Australasian College of Surgeons
National Breast and Ovarian Cancer Centre and Royal Australasian College of Surgeons National Breast Cancer Audit Public Health Monitoring Series 2008 Data Published August 2010 National Breast and Ovarian
More informationUnderstanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide A diagnosis of breast cancer is never easy, but today there are more treatment options than ever before. A breast
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Pre-authorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Pre-authorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: February 24, 2012 Revised:
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationBRACHYTHERAPY FOR TREATMENT OF BREAST CANCER
BRACHYTHERAPY FOR TREATMENT OF BREAST CANCER Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationIpsilateral In-Breast Tumor Relapse after Breast Conservation Therapy: True Recurrence Versus New Primary Tumor
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No., September: 18-19, 6 Ipsilateral In-Breast Tumor Relapse after Breast Conservation Therapy: True Recurrence Versus New Primary Tumor HASSAN M. ABD-ALLA,
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationDuctal carcinoma in situ (DCIS) is a heterogeneous disease that currently accounts for approximately 20% of all
Predictors of Invasive Breast Cancer in Patients with an Initial Diagnosis of Ductal Carcinoma in Situ: A Guide to Selective Use of Sentinel Lymph Node Biopsy in Management of Ductal Carcinoma in Situ
More informationDuctal carcinoma in situ (DCIS)
DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made
More informationCorporate Medical Policy Brachytherapy Treatment of Breast Cancer
Corporate Medical Policy Brachytherapy Treatment of Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_treatment_of_breast_cancer 7/1996 5/2015 5/2016 5/2015
More informationAudit. Process for managing outliers in breast cancer surgery. March 2005
Process for managing outliers in breast cancer surgery Audit March 2005 Prepared by: Australian Safety & Efficacy Register of New Interventional Procedures Surgical On behalf of: The Section of Breast
More informationBreast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies
Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [For the list of services and procedures that need preauthorization, please refer to www.mcs.pr Go to Comunicados a Proveedores, and click
More informationDuctal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes
DOI: 10.1093/jnci/djp482 Advance Access publication on January 13, 2010. The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationNicole Kounalakis, MD
Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations
More informationThe effects of hormone replacement therapy on postmenopausal breast cancer biology and survival
The American Journal of Surgery (2009) 197, 403 407 The Midwest Surgical Association The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival Stephen F. Sener, M.D.*,
More informationStudy Design and Statistical Analysis
Study Design and Statistical Analysis Anny H Xiang, PhD Department of Preventive Medicine University of Southern California Outline Designing Clinical Research Studies Statistical Data Analysis Designing
More informationwww.downstatesurgery.org
Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills
More informationRecommendations for the management of early breast cancer
Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationClinical trial enrollment among older cancer patients
Clinical trial enrollment among older cancer patients Sharon H. Giordano MD, MPH Professor, Health Services Research Mariana Chavez Mac Gregor MD, MSc Assistant Professor, Breast Medical Oncology Department
More informationAddressing overtreatment of ductal carcinoma in situ (DCIS): a qualitative study of how terminology affects women s concern and treatment preferences
Addressing overtreatment of ductal carcinoma in situ (DCIS): a qualitative study of how terminology affects women s concern and treatment preferences SYDNEY MEDICAL SCHOOL Brooke Nickel Alexandra Barratt,
More informationTravel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationShould I Continue Having Mammograms to Screen for Breast Cancer? A decision aid for women aged 70 and older at their next screening mammogram.
Should I Continue Having Mammograms to Screen for Breast Cancer? A decision aid for women aged 70 and older at their next screening mammogram. AUSTRALIAN SCREENING MAMMOGRAPHY DECISION AID TRIAL Why is
More informationOutcome analysis of breast cancer patients who declined evidence-based treatment
Joseph et al. World Journal of Surgical Oncology 2012, 10:118 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Outcome analysis of breast cancer patients who declined evidence-based treatment Kurian
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationBreast Cancer Accelerated Partial Breast Irradiation Bruce G. Haffty, MD Professor and Chairman Dept Radiation Oncology UMDNJ-RWJMS Cancer Institute
Breast Cancer Accelerated Partial Breast Irradiation Bruce G. Haffty, MD Professor and Chairman Dept Radiation Oncology UMDNJ-RWJMS Cancer Institute of New Jersey Rationale for Partial Breast Radiation
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationUnderstanding the Impact of Breast Reconstruction on the Surgical Decision-Making Process for Breast Cancer
489 Understanding the Impact of Breast Reconstruction on the Surgical Decision-Making Process for Breast Cancer Amy K. Alderman, MD, MPH 1,2 Sarah T. Hawley, PhD 2,3 Jennifer Waljee, MD 4 Mahasin Mujahid,
More informationCurrent view on ductal carcinoma in situ and importance of the margin thresholds: A review
Facts Views Vis Obgyn, 2014, 6 (4): 210-218 Review Current view on ductal carcinoma in situ and importance of the margin thresholds: A review A. Van Cleef 1, S. Altintas 2, M. Huizing 2, K. Papadimitriou
More informationEvaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003
Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal
More informationHandheld Radiofrequency Spectroscopy for Intraoperative Margin Assessment During Breast-Conserving Surgery
Handheld Radiofrequency Spectroscopy for Intraoperative Margin Assessment During Breast-Conserving Surgery Assessment Program Volume 28, No. 4 August 2013 Executive Summary Background Breast-conserving
More informationBreast Cancer Care & Research
Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationHow To Use A Breast Cancer Test To Help You Choose Chemotherapy
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationBreast. Patient information. cancer clinical pathway
Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather
More informationBreast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report
Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT Five-year report Community Health Pathology Southern Area Health Service ACT Health General Practitioners Nurses Social
More informationBreast Cancer Management Clinical Guidelines. Prepared by the Clinical Guidelines Committee Royal College of Surgeons in Ireland November 2000
Breast Cancer Management Clinical Guidelines Prepared by the Clinical Guidelines Committee Royal College of Surgeons in Ireland November 2000 Mr. T. N. Walsh Prof. N. O Higgins Mr. T. N. Walsh Senior Lecturer
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More information